Here’s what you should know.
1. Takeda announced the acquisition on Jan. 9, 2017.
2. The acquisition was the target of an investigation from New York City-based Faruqi & Faruqi. The law firm investigated whether Ariad properly executed fair sale practices.
3. Takeda’s President and CEO Christophe Weber said, “We are very pleased to have completed the acquisition of ARIAD Pharmaceuticals. The addition of ARIAD’s innovative targeted therapies and research and development capabilities strengthens and diversifies our oncology business, positioning Takeda for sustainable long-term growth in this priority therapeutic area.”
More articles on gastroenterology/endoscopy:
Thieves steal $1.2M in endoscopy equipment from Toronto hospital: 5 insights
GI leader to know: Dr. Antonio Caos of Platte Valley Medical Group
GI leader to know: Dr. James Singer of Arizona Digestive Health
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
